Oklahoma City's EpimedX biotech says new drug offers treatment for sickle cell disease
A local Oklahoma City biotech company wants to provide an effective and safe treatment for sickle cell disease, and it believes it has a drug that will do just that.
EpimedX developed Edx-17 with pharmaceuticals company VBS. The compound is used currently in agriculture for weatherization, but has been declared safe for humans by the FDA. While the drug is being developed to treat sickle cell disease, it shows promise for use in treating malaria as well.
The company has completed a round of angel investor funding with the help of the technology development nonprofit i2E and is working to identify funding for clinical trials.